Ikena Oncology, Inc. SEC filings document the former IKNA oncology issuer, its clinical-development disclosures, and its later corporate transition under the name neBio, Inc. The filings include material-event reports, material agreements, shareholder voting matters, capital-structure disclosures, operating and financial results, and risk and clinical-regulatory updates.
Recent Form 8-K disclosures also record governance and reporting matters, including an independent auditor change, equity inducement plan disclosures, compensation-plan documentation, and registered common stock identified under the IMA symbol on The Nasdaq Capital Market.
Ikena Oncology filed an 8-K announcing a 1-for-12 reverse stock split of its common stock, effective at the start of trading on 28 Jul 2025. Every 12 pre-split shares will convert into 1 post-split share; fractional shares will be paid out in cash based on Nasdaq’s 24 Jul 2025 closing price. The split will reduce outstanding shares from approximately 48.2 million to roughly 4 million, while authorised share capital and the $0.001 par value remain unchanged; exercise prices and share counts under outstanding equity awards will be adjusted proportionately.
At the same time the company will rebrand as ImageneBio, Inc., adopt the new ticker IMA, and switch CUSIP to 45175G207, continuing to trade on the Nasdaq Capital Market. Computershare is serving as exchange agent, and shareholders whose holdings are in book-entry or brokerage accounts need not take any action.
The filing is limited to corporate-action details and a comprehensive forward-looking-statement section that highlights risks surrounding the planned merger with Inmagene Biopharmaceuticals, the concurrent financing, and completion of the reverse split. No financial performance metrics were provided.